1. LCDC. Recommendations for prevention of HIV transmission
in health care settings. CDWR 1987;13S3:1-10.
2. LCDC. Update: universal precautions for prevention
transmission of human immunodeficiency virus, hepatitis B virus and other
bloodborne pathogens in health care settings. CDWR 1988;14:117-24.
3. LCDC. Universal precautions: report of a consensus
meeting. CCWR 1989;15:23-8.
4. LCDC. Bloodborne pathogens in the health care setting:
risk for transmission. CCDR 1992;18:177-84.
5. LCDC. Infection Control Guidelines: preventing
the transmission of bloodborne pathogens in health care settings. CCDR
1997. In press.
6. Holton D. Nationally recognized protocols: vaccination
against hepatitis B. In: National symposium on risk and prevention of
infectious diseases for emergency response personnel, Ottawa, ON, September
27-28, 1994. LCDC 1994:31-3.
7. National Advisory Committee on Immunization. A
guide to immunization for Canadians. LCDC 1984:90-1. (Supply and Services
Canada, Cat. No. H49-8/1980.)
8. LCDC. Guidelines for counselling persons who have
had an occupational exposure to human immunodeficiency virus. CCDR 1990;16S2:1-12.
9. LCDC. Prevention and control of hepatitis C: guidelines
and recommendations. CCDR 1995;21S2:1-18.
10. Henderson D. Post-exposure prophylaxis for occupational
exposures to hepatitis B, hepatitis C, and human immunodeficiency virus.
Surg Clin North Am 1995;75:1175-87.
11. Peterson LR, Satten GA, Dodd R et al. Duration
of time from onset of human immunodeficiency virus type 1 infectiousness
to development of detectable antibody. Transfusion 1994;34:283-89.
12. Horsburgh CR Jr, Jason J, Longini IM Jr et al. Duration
of human immunodeficiency virus infection before detection of antibody.
Lancet 1989;II:637-40.
13. Anonymous. Double-deadly needlestick transmits
HIV and HCV: delayed seroconversion raises follow-up questions. Hospital
Infection Control 1996;23:77.
14. National Advisory Committee on Immunization. Canadian
immunization guide. 4th ed. Ottawa, ON: Health Canada, 1993:54. (Supply
and Services Canada, Cat. No. H49-8/1993E.)
15. Canadian AIDS Society. Safer sex guidelines:
healthy sexuality and HIV. Revised ed. 1994.
16. CDC. Public Health Service statement on management
of occupational exposure to human immunodeficiency virus, including considerations
regarding zidovudine postexposure use. MMWR 1990;39:1-14.
17. Ricketts MN, Robillard P, Roy E. Management of
occupational exposure to human immunodeficiency virus. Pract Allerg Immunol
1995;10:92-98.
18. Gerberding JL. Management of occupational exposures
to blood-borne viruses. N Engl J Med 1995;332:444-51.
19. CDC. Case-control study of HIV seroconversion
in health care workers after percutaneous exposure to HIV-infected blood
- France, United Kingdom, and United States, January 1988-August 1994.
MMWR 1995;44:929-33.
20. Tokars JI, Marcus R, Culver DH et al. Surveillance
of HIV infection and zidovudine use among health care workers after occupational
exposure to HIV-infected blood. Ann Intern Med 1993;118:913-19.
21. Connor EM, Sperling RS, Gelber R et al. Reduction
of maternal-infant transmission of human immunodeficiency virus type 1 with
zidovudine treatment. N Engl J Med 1994;331:1173-80.
22. Niu MT, Stein DS, Schnittmann SM. Primary human
immunodeficiency virus type 1 infection: review of pathogenesis and early
treatment interventions in humans and animal retrovirus infections. J
Infect Dis 1993;168:1490-501.
23. Tsai CC, Follis KE, Sabo A et al. Prevention
of HIV infection in macaques by (R)-9-(2- phosphonylmethoxypropyl) adenine.
Science 1995;270:1197-99.
24. Anonymous. New drugs for HIV infection. The
Medical Letter on Drugs and Therapeutics 1996;38:35-7.
25. Carpenter CCJ, Fischl MA, Hammer SM et al. Antiretroviral
therapy for HIV infection in 1996: recommendations of an international panel.
JAMA 1996;276:146-54.
26. CDC. Update: provisional public health service
recommendations for chemoprophylaxis after occupational exposure to HIV.
MMWR 1996;45:468-72.
